glp 1 in obesity The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer | Cancer and Metastasis Reviews PDF] GLP-1 Based Combination Therapy
Description
doi: 10.1016/0026-0495(78)90045-8
![glp 1 in obesity The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer | Cancer and Metastasis Reviews PDF] GLP-1 Based Combination Therapy](https://ai2-s2-public.s3.amazonaws.com/figures/2017-08-08/73983626886b6439761b6844997806367e881df8/3-Figure1-1.png)
Several studies have identified an association between semaglutide use and a higher incidence of NAION, although researchers continue to examine the biological mechanisms involved and whether other patient-specific risk factors contribute to the condition
Coordinating with endocrinology or gynecology can help optimize the overall approach
![glp 1 in obesity The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer | Cancer and Metastasis Reviews PDF] GLP-1 Based Combination Therapy](https://f6publishing.blob.core.windows.net/3982523e-43f6-4326-be26-a59848180a60/WJD-7-572-g008.jpg)
When researchers used computer statistical modeling to see what could happen after more than a year off of the medications, it suggested those patients could regain about 75% of the weight they had lost
![glp 1 in obesity The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer | Cancer and Metastasis Reviews PDF] GLP-1 Based Combination Therapy](https://www.immune-system-research.com/wp-content/uploads/2024/07/Semaglutide-is-a-GLP-1-Receptor-Agonist-for-T2DM-and-Obesity-Research-20240730.jpg)